Cbp-501 clinical trials
Also written CBP501.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses cbp-501 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CBP501
- 2
Studies by the year they started
5 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2017 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
CanBas Co. Ltd. (5)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses cbp-501 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic CancerCompletedPhase 2CanBas Co. Ltd.NCT04953962Written as CBP501 (16)How we know
- Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)CompletedPhase 1/2CanBas Co. Ltd.NCT00700336Written as pemetrexed, cisplatin and CBP501How we know
- CBP501, Cisplatin and Nivolumab in Advanced Refractory TumorsCompletedPhase 1CanBas Co. Ltd.NCT03113188Written as CBP501How we know
- Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)CompletedPhase 2CanBas Co. Ltd.NCT00942825Written as CBP501 + Cisplatin + PemetrexedHow we know
- Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid TumorsCompletedPhase 1CanBas Co. Ltd.NCT00551512Written as CBP501 and CisplatinHow we know
Codes
What other systems call cbp-501 · ClinicalTrials.gg INT005048
- UNII (FDA) XH2662798ICBP-501Confirmed FDA, Wikidata
- Wikidata Q27293833cbp-501Confirmed FDA, Wikidata
- DrugBank DB17277One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XH2662798I | CBP-501 | Confirmed FDA, Wikidata |
| Wikidata | Q27293833 | cbp-501 | Confirmed FDA, Wikidata |
| DrugBank | DB17277 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.